Tergus Pharma

TergusPharma.com

Tergus Pharma is a dermatology-focused organization offering complete pharmaceutical product development services to the pharmaceutical and biotechnology industries utilizing in-vitro penetration models and other scientific tools. Tergus Pharma operates from its cGMP compliant, state of the art facilities based in Research Triangle Park (RTP), North Carolina.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

A NOVEL AZAPEPTIDE EDITING METHOD PROVIDES POTENTIAL FOR NEW DRUG DEVELOPMENT, FEINSTEIN INSTITUTES RESEARCH SHOWS

Feinstein Institutes | November 29, 2022

news image

Peptides, short sections of proteins made up of chains of amino acids, are an important area of new drug development due to their potential for increased specificity and fewer side effects. Their main drawback is the rapid degradation by the body’s own enzymes, which has led to the need to develop longer-lasting peptide alternatives. Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir. A new ...

Read More

Research

PFIZER AND BIONTECH NAB COVID-19 VACCINE AUTHORIZATION FROM U.K. FOR FIRST-EVER MARKETED MRNA SHOT

Pfizer | December 03, 2020

news image

The two organizations' BNT162b2 has become the primary COVID-19 immunization permitted in the Western world as medication controllers in the U.K. given out a crisis use approval on Wednesday, in front of choices by the U.S. also, Europe, which are normal soon. For the more extensive immunization world, the Medicines and Healthcare items Regulatory Agency's choice methods the world currently has the principal mRNA shot approved for far reaching use, opening up a fresh out o...

Read More

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

news image

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

news image

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More
news image

Pharmacy Market

A NOVEL AZAPEPTIDE EDITING METHOD PROVIDES POTENTIAL FOR NEW DRUG DEVELOPMENT, FEINSTEIN INSTITUTES RESEARCH SHOWS

Feinstein Institutes | November 29, 2022

Peptides, short sections of proteins made up of chains of amino acids, are an important area of new drug development due to their potential for increased specificity and fewer side effects. Their main drawback is the rapid degradation by the body’s own enzymes, which has led to the need to develop longer-lasting peptide alternatives. Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir. A new ...

Read More
news image

Research

PFIZER AND BIONTECH NAB COVID-19 VACCINE AUTHORIZATION FROM U.K. FOR FIRST-EVER MARKETED MRNA SHOT

Pfizer | December 03, 2020

The two organizations' BNT162b2 has become the primary COVID-19 immunization permitted in the Western world as medication controllers in the U.K. given out a crisis use approval on Wednesday, in front of choices by the U.S. also, Europe, which are normal soon. For the more extensive immunization world, the Medicines and Healthcare items Regulatory Agency's choice methods the world currently has the principal mRNA shot approved for far reaching use, opening up a fresh out o...

Read More
news image

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More
news image

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us